hero section gradient
12 handpicked stocks

Defence Stocks

These carefully selected defence companies are positioned to benefit from increasing global tensions and military spending. Our professional analysts have identified stocks with potential growth from long-term government contracts and enhanced defence initiatives.

Author avatar

Han Tan | Market Analyst

Published on May 28

Your Basket's Financial Footprint

Aggregate market capitalisation and breakdown for the 'Defence Stocks' basket, with investor key takeaways.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and a tendency to track broader market movements, reducing idiosyncratic risk.
  • Consider this basket as a core portfolio holding rather than a speculative growth position.
  • Likely to deliver steady long-term value rather than explosive short-term gains.
Total Market Cap
  • PLTR: $430.42B

  • LMT: $113.27B

  • NOC: $85.54B

  • Other

About This Group of Stocks

1

Our Expert Thinking

As global conflicts escalate, governments worldwide are increasing military budgets to strengthen defence capabilities. This creates sustained demand for weapons systems, cybersecurity, and defence technology, potentially benefiting companies with established government relationships.

2

What You Need to Know

Defence stocks often show stability during economic uncertainty due to long-term government contracts. These companies typically provide essential services ranging from aerospace engineering to cybersecurity, with revenue streams that can remain consistent despite market volatility.

3

Why These Stocks

This collection features established defence contractors with strong government relationships and innovative capabilities. These handpicked companies represent diverse aspects of the defence industry, from aerospace giants to emerging tech firms specializing in security solutions.

Why You'll Want to Watch These Stocks

🌍

Global Tensions Creating Opportunity

Rising geopolitical conflicts are driving nations to increase defence budgets, potentially creating sustained demand for the products and services these companies provide.

🔒

Recession-Resistant Potential

Defence contractors often benefit from long-term government contracts that can provide revenue stability even during economic downturns, making them interesting during uncertain times.

🚀

Technology Evolution Advantage

Many of these defence companies are at the forefront of developing cutting-edge security technologies that governments increasingly need in our complex global landscape.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Tech Stocks (AI Valuation Reset) Present Potential Entry

Tech Stocks (AI Valuation Reset) Present Potential Entry

Recent market turmoil, driven by concerns over AI stock valuations, has led to a significant drop in global markets. This correction creates a potential opportunity to invest in fundamentally sound technology companies at more attractive prices.

Walmart Succession Plan Explained | Market Effects

Walmart Succession Plan Explained | Market Effects

Walmart announced a CEO transition, with veteran John Furner taking the helm, which could create opportunities for competitors. This leadership change at a retail giant may cause short-term uncertainty, potentially benefiting other major players in the retail space.

Biotech Buyout Candidates (Post-Merck Acquisition)

Biotech Buyout Candidates (Post-Merck Acquisition)

Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.

Frequently Asked Questions